AR and posterior cortical atrophy: Since it is likely that combinations of chemotherapeutic agents will be required for effective treatment of CRPC1,2, we determined whether combining BA with the FDA approved AR antagonist Enz is useful against PCa and CRPC cells, especially if resistant to Enz.